The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: A population‐based study in Western Sweden
Open accessAbstract
BACKGROUND: Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria and have led to the development of molecularly targeted drug therapy. New treatment options mandate more accurate information regarding the incidence, prevalence, clinical behavior, and prognostic factors of GIST. METHODS: All patients ( n = 1460) who potentially had GIST diagnosed from 1983 to 2000 in western Sweden (population, 1.3–1.6 million) were reviewed, and 288 patients with primary GIST were identified. The incidence and prevalence of GIST were determined, and predictive prognostic factors, including current risk‐group stratifications, were analyzed statistically. RESULTS: Ninety percent of GISTs were detected clinically due to symptoms (69%) or were incidental findings at surgery (21%); the remaining 10% of GISTs were found at autopsy. Forty‐four percent of symptomatic, clinically detected GISTs were categorized as high risk (29%) or overtly malignant (15%), with tumor‐related deaths occurring in 63% of patients and 83% of patients, respectively (estimated median survival, of 40 months and 16 months, respectively). Tumor‐related deaths occurred in only 2 of 170 of patients (1.2%) with very‐low‐risk, low‐risk, or intermediate‐risk tumors. The annual incidence of GIST was 14.5 per million. The prevalence of all GIST risk groups was 129 per million (31 per million for the high‐risk group and the overtly malignant group). CONCLUSIONS: GIST has been under recognized: Its incidence, prevalence, and clinical aggressiveness also have been underestimated. Currently existing risk‐group stratification systems based on tumor size and mitotic rate delineate GIST patients who have a poor prognosis. Prognostication in patients with GIST can be refined using a proposed risk score based solely on tumor size and proliferative index. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oritinib overcomes T790M-mediated drug resistance in NSCLC and inhibits WT-EGFR, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750, and EGFRd746-750/T790M kinases, with IC50 values of 18, 0.7, 4, 0.1, 1.4, and 0.89 nM, respectively.
“Oritinib overcomes T790M-mediated drug resistance in NSCLC and inhibits WT-EGFR, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750, and EGFRd746-750/T790M kinases. IC50 were 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [165]
Oritinib binds irreversibly to EGFR kinase by covalently bonding to Cys797 residues targeting ATP binding sites.
“Oritinib binds irreversibly to EGFR kinase by covalently bonding to form Cys797 residues targeting ATP binding sites.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [165]
Oritinib effectively and selectively targets mutated EGFR cell lines in vitro.
“Oritinib effectively and selectively targets mutated EGFR cell lines in vitro.142,163–165”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,487
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
Diagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. �., Berman, J. J., Corless, C. L., Gorstein, F., Lasota, J. P., Longley, B. J., Miettinen, M., O’Leary, T. J., Remotti, H. E., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,439
Two Hundred Gastrointestinal Stromal Tumors
DeMatteo, R. P., Lewis, J. J., Leung, D. H. Y., Mudan, S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,541
Joensuu, H., Roberts, P., Sarlomo‐Rikala, M., Andersson, L. C., Tervahartiala, P. O., Tuveson, D. A., Silberman, S., Capdeville, R., Dimitrijević, S., Druker, B. J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,030
Miettinen, M., & Lasota, J. P. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000338 · Cited by 1,865
Kindblom, L. G., Remotti, H. E., Aldenborg, F., et al. (1998) · PubMed · Cited by 1,677
Self-citationvan Oosterom, A. T., Judson, I. R., Verweij, J., Stroobants, S. G., Paola, E. D. D., Dimitrijević, S., Martens, M., Webb, A., Sciot, R., Glabbeke, M. M. V., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,258
Heinrich, M. C., Griffith, D., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,066
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A. U., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., et al. (2001) · PubMed · Cited by 959
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D. �., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 687
Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review
Miettinen, M., El-Rifai, W. M., Leslie, H., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.124123 · Cited by 668
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C.-J., Maclure, T., Demetri, G. D., Xiao, S., Singer, S., Fletcher, C. D. �., & Fletcher, J. A. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64946-2 · Cited by 639
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
DeMatteo, R. P., Heinrich, M. C., El-Rifai, W. M., & Demetri, G. D. (2002) · Human Pathology · doi:10.1053/hupa.2002.124122 · Cited by 635
Heinrich, M. C., Blanke, C. D., Druker, B. J., & Corless, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1692 · Cited by 630
Management of malignant gastrointestinal stromal tumours
Joensuu, H., Fletcher, C. D. �., Dimitrijević, S., Silberman, S., Roberts, P., & Demetri, G. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00899-9 · Cited by 568
Corless, C. L., McGreevey, L. S., Haley, A., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61103-0 · Cited by 446
Heinrich, M. C., Blanke, C. D., Druker, B. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1692 · Cited by 354
Gastrointestinal Stromal Tumors
Suster, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-42632-7 · Cited by 164
Stromal Tumors of the Duodenum A Histologic and Immunohistochemical Study of 20 Cases
Goldblum, J. R., & Appelman, H. D. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199501000-00009 · Cited by 147
Rudolph, P., Gloeckner‐Hofmann, K., Parwaresch, R. M., Harms, D., & Schmidt, D. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90447-6 · Cited by 145
Stromal Tumors of the Jejunum and Ileum
Brainard, J., & Goldblum, J. R. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199704000-00006 · Cited by 127
Statistical methods in cancer research
Gardner, B. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1170.abs · Cited by 122
Panizo-Santos, Á., Sola, I., Vega, F., de Álava, E., Lozano, M. D., Idoate, M. A., & Pardo‐Mindán, J. (2000) · International Journal of Surgical Pathology · doi:10.1177/106689690000800208 · Cited by 79
Gastrointestinal Stromal Tumors
Somaiah, N., Gupta, R., & PATEL, S. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_17 · Cited by 3
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1002/1097-0142(19950101)75:1 <154::AID-CNCR2820751305>3.0.CO;2-Z · DOI
- Emory TS, 1997, Ki‐67 (MIB‐1) immunohistochemistry as a prognostic factor in gastrointestinal smooth‐muscle tumors, J Surg Pathol., 239
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Metadata
- Authors
- Nilsson, B., Bümming, P., Meis‐Kindblom, J. M., Odén, A., Dortok, A., Gustavsson, B., Sablinska, K., & Kindblom, L.
- Affiliations
- University of Gothenburg (SE)
- Novartis (United States) (US)
- Novartis (Switzerland) (CH)
- Corresponding author
- Kindblom, Lars‐Gunnar
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-02-03
- Volume
- 103
- Issue
- 4
- Pages
- 821-829
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1981491302
- Cited by
- 1,272
- References
- 26
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 35 · 2023: 51 · 2022: 74 · 2021: 48 · 2020: 49 · 2019: 62 · 2018: 62 · 2017: 52 · 2016: 50 · 2015: 79 · 2014: 74 · 2013: 80 · 2012: 78
- FWCI
- 51.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Novartis Oncology, Stockholm, Sweden
- Swedish Cancer Society
- Johan Jansson Foundation
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- gastrointestinal stromal tumor, incidence, prevalence, prognostic factors, risk stratification, tumor size, mitotic activity, survival, tumor-related mortality, risk score
- MeSH terms
- Imatinib Mesylate, Age Factors, Antineoplastic Agents, Benzamides, Humans, Piperazines, Prognosis, Pyrimidines, Retrospective Studies, Risk Factors, Digestive System Surgical Procedures, Sweden, Incidence, Prevalence, Survival Analysis, Ki-67 Antigen, Gastrointestinal Stromal Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
